ClinicalTrials.gg
RecruitingNCT05944029Updated Jul 13, 2023

Effect of Pomegranate Seed Powder on Markers of Metabolic Syndrome

An interventional study of Pomegranate seed powder in Metabolic Syndrome, sponsored by Asif Ali. Recruiting at 1 site in Pakistan. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-07-13.

Sponsored by Asif Ali · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2023, 3 years 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
30 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Metabolic Syndrome with a site in Pakistan — 6 open to participants now, 7 under way, none of them phase 3. Metabolic Syndrome · Pakistan.

Planned enrollment
12th of 16
50 · median 60
Started
2023
with 2 others
No phase
14 of 16
6 open now
Registered
5th of 16
by date
Lead sponsor
1 of 16
Asif Ali

Among the 16 studies in Metabolic Syndrome with a site in Pakistan, this one is the 12th largest by planned enrollment, is one of 3 that started in 2023, is one of 14 with no phase, and was the 5th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

6 of the 16 studies in Metabolic Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 30 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Metabolic Syndrome with a site in Pakistan, or all of them as a file.
02

Study summary

Metabolic syndrome is a public health concern worldwide and in Pakistan as well. Abdominal obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low HDL cholesterol are its hallmarks while pomegranate seed's unique chemical composition has sparked research into the health benefits in same arena as weight control, blood lipid profile changes, and other metabolic disturbances. It's high time to study therapeutic efficiency of Pomegranate seed powder against metabolic syndrome.

Read the detailed description

Metabolic syndrome, accumulation of certain metabolic risk factors, such as abdominal obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low HDL cholesterol, has been noted as one of the most important risk factors for the epidemic of type 2 diabetes and cardiovascular disease in the 21st century. It has become a significant public health concern and a global epidemic with a prevalence rate of about 25% among American adults. Multiple researches have demonstrated the effectiveness of pomegranate in the management of diabetes, inflammatory conditions, obesity, and blood lipid levels, and consequently metabolic syndrome. Various pomegranate components have the potential to substitute anti-diabetic medications as well Pomegranate seed's unique chemical composition has sparked research into the health benefits, such as weight control, blood lipid profile changes, and other metabolic disorders.

seed powder can influence the patient's metabolic syndrome-related indicators.

Hypothesis:

Pomegranate seed powder can be effective to treat the individuals with impaired metabolism.

Methodology:

In a clinical trial, patients of metabolic syndrome (n=50) will be given pomegranate seed powder dose for over 8 weeks, twice a day. Biochemical outcomes including blood pressure, FBG, cholesterol, hemoglobin level will be determined before and after the completion of trial in addition to patient's weight. Finally, using one-way ANOVA and T-test, collected data will be analyzed.

Expected outcome: The study will explore the potential of pomegranate seed powder in treating metabolic syndrome's risk factors. Therefore, our findings on the studied parameters of patient will assist future researchers in developing tested, evidence-based recommendations.

03

Conditions studied

  • Metabolic Syndrome

Keywords

  • Metabolic Syndrome
  • Hypertension
  • Obesity
  • Insulin Resistance
  • Diabetes
  • Pomegranate seed powder
  • Dyslipidemia
04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 25kg/m2
  • Dyslipidemia
  • Altered blood glucose level
  • Age 30-55 ( male and female)

Exclusion criteria

Exclusion Criteria:

  • Thyroid disorder
  • Liver disease
  • Kidney disorder
  • Cancer etc
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Metabolic syndrome Patients

    Pomegranate seed powder is administered for alleviating symptoms of metabolic syndrome

    Dietary Supplement: Pomegranate seed powder

Interventions

  • Dietary supplementPomegranate seed powder

    10 g powder / day

    Also known as: Punica granatum

06

What researchers measure

Primary outcomes

  1. Lipid Profile

    The change in Lipid Profile, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.

    Time frame: 7 weeks

  2. Fasting Glucose

    The change in Blood Glucose level, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.

    Time frame: 7 weeks

  3. Blood Pressure

    The change in both systolic and diastolic blood pressure after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.

    Time frame: 7 weeks

  4. Weight

    The change in weight, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.

    Time frame: 7 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Intervention study, data will be confidential to maintain patients privacy, enrollment of patients with their consent

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jul 2023, 5 months after the start.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 5 months is below that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2023
First posted
Jul 13, 2023
StartActual
Feb 20, 2023
Primary completionEst.
Jul 20, 2023
CompletionEst.
Aug 24, 2023
Last update
Jul 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05944029
Lead sponsor
Asif Ali
Responsible party
Asif Ali (Researcher, University of Veterinary and Animal Sciences, Lahore - Pakistan) — Sponsor-investigator
First posted
Jul 13, 2023
Start date
Feb 20, 2023
Primary completion
Jul 20, 2023 (estimated)
Completion
Aug 24, 2023 (estimated)
Last update
Jul 13, 2023

Study contacts

Shahbano Zahid, Mphil
Contact
shahbanozahid265@gmail.com
+923095563643
Dr. Asif Ali, PhD
Contact
asif.ali@uvas.edu.pk
+923017151530 ext. 296
Dr. Asif Ali, Mphil
study director · University of Veterinary and Animal Sciences Lahore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion